Reconstructing mandibular defects with bioengineered tooth and bone

Apr 06, 2008

Current strategies for jaw reconstruction require multiple procedures, first to repair the bone defect to offer sufficient support, and then to place the tooth implant. The entire procedure can be painful and time-consuming, and the desired esthetic and functional repair can be achieved only when both steps are successful.

Although the patient’s quality of life can be improved significantly, the prognosis is often unpredictable, especially in young patients, whose jaws continue to grow, while the implant remains fixed. The ability to bioengineer combined tooth and bone constructs, which would grow in a coordinated fashion with the surrounding tissues, could potentially improve the clinical outcomes, and also reduce patient suffering.

Under the guidance of Dr. Pamela C. Yelick, a research team at Tufts University (Boston, MA) has examined the feasibility of simultaneously reconstructing both teeth and bone. In 2002, the group first reported the regeneration of tooth crowns, from cultured tooth bud cells seeded onto biodegradable scaffolds and implanted into rat hosts.

The morphology of the developing tissue-engineered tooth crowns closely resembled that of naturally formed teeth. Next, they generated a hybrid tooth-bone construct, by combining a bone-marrow-derived stem-cell-seeded scaffold with the previously used tooth model, implanted and grown in the omenta (tissues connecting abdominal structures) of rat hosts.

In this case, the formation of not only the tooth crowns but also tooth root and surrounding alveolar bone was observed. However, since the omentum offers an environment quite distinct from that of the natural tooth site, the jawbone, the team examined hybrid tooth-bone construct development using third molar tooth bud cells and bone marrow derived from, and implanted back into, the same minipig.

Their results showed the formation of organized bioengineered dental tissues closely resembling those of naturally formed teeth, including dentin, enamel, pulp, and periodontal ligament, after 12 weeks of implantation. Further analyses confirmed the expression of tooth- and bone-specific markers on the bioengineered tissues. In addition, they observed novel mineralized tissue interface formation, including enamel/bone and dentin/bone interfaces.

These results demonstrate the feasibility and therapeutic potential for regenerating tooth and bone from autologous stem cells, for craniofacial reconstructions in humans. This model is currently being modified to improve alveolar bone formation, regenerated dental tissue orientation, tooth root development, and tooth eruption.

Source: International & American Association for Dental Research

Explore further: Using feminist theory to understand male rape

add to favorites email to friend print save as pdf

Related Stories

Glass helps damaged bone regenerate

Apr 13, 2010

(PhysOrg.com) -- A prosthodontist from Egypt is helping Lehigh researchers develop bioactive glass that mimics the behavior of living tissue.

Recommended for you

Using feminist theory to understand male rape

3 hours ago

Decades of feminist research have framed rape and sexual assault as a 'women's issue', leaving little room for the experiences of male victims. But a new study published in the Journal of Gender Studies suggests that feminist ...

Simulation-based training improves endoscopy execution

Oct 18, 2014

(HealthDay)—Simulation-based training (SBT) improves clinicians' performance of gastrointestinal endoscopy in both test settings and clinical practice, according to research published in the October issue ...

Data sharing in pharmaceutical industry shows progress

Oct 16, 2014

To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

Swiss drug maker Roche posts flat 3Q sales

Oct 16, 2014

(AP)—Swiss drugmaker Roche Holding AG has reported "stable" or flat sales for the first nine months of 2013 but says the results show strong demand for its cancer drugs and emerging new products.

User comments : 0